Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates
Background To update the Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer, the same panelists as in the previous consensus panel held a series of meetings to discuss updated clinical evidence and experiences. Method...
Gespeichert in:
| Veröffentlicht in: | Asia-Pacific journal of clinical oncology 2021-04, Vol.17 (S3), p.12-26 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 26 |
|---|---|
| container_issue | S3 |
| container_start_page | 12 |
| container_title | Asia-Pacific journal of clinical oncology |
| container_volume | 17 |
| creator | Poon, Darren Ming‐Chun Chan, Chi‐Kwok Chan, Tim‐Wai Cheung, Foon‐Yiu Ho, Lap‐Yin Kwong, Philip Wai‐Kay Lee, Eric Ka‐Chai Leung, Angus Kwong‐Chuen Leung, Simon Yiu‐Lam So, Hing‐Shing Tam, Po‐Chor Ma, Wai‐Kit |
| description | Background
To update the Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer, the same panelists as in the previous consensus panel held a series of meetings to discuss updated clinical evidence and experiences.
Methods
The previous consensus statements were retained, deleted, or revised, and new statements were added. At the final meeting, all statements were reviewed and amended as appropriate, followed by panel voting.
Results
There were significant changes and additions to the previous consensus statements, primarily driven by the advances in androgen receptor signaling inhibitors, treatment sequencing in metastatic castration‐resistant prostate cancer, and increasing recognition of oligometastatic prostate cancer since the introduction of prostate‐specific membrane antigen positron emission tomography. In this update, a total of 59 consensus statements were accepted and established.
Conclusions
The consensus panel updated consensus statements on the management of advanced prostate cancer, aiming to allow physicians in the region to keep abreast of the recent evidence on optimal clinical practices. |
| doi_str_mv | 10.1111/ajco.13580 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2514603611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2512941925</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3930-b5faf67aeed939347d00afe2f4493aa0536fac272dc39078b9dac9fa26992983</originalsourceid><addsrcrecordid>eNp9kctKAzEUhoMo3jc-gATciFDNZTLTLEtR6wW6UNfDaSapU2aSOplRuusjCLrw-fokZlov4MIskpOf7_yc5EfogJJTGtYZTJQ7pVx0yRrapknEO4mI-fpPLcQW2vF-QgiXTNJNtMV5NyZxJLbRx8DZMb5pt4fKFW6cKyhwz3uncqhzZxfzt1_kLqi6nmFnWnoxfx1a1TbNsHLWa-sbj30NtS61rT12FtePGpdgYbyU2kbInsEqneFp5ZYsVu29WszfGaESP0yzIPo9tGGg8Hr_69xF9xfn9_1B53Z4edXv3XYUl5x0RsKAiRPQOpNBiJKMEDCamSiSHIAIHhtQLGFZ4EnSHckMlDTAYhn-ost30fHKNkzz1Ghfp2XulS4KsNo1PmWCRjHhMaUBPfqDTlxT2TBcSzEZUclEoE5WlArP85U26bTKS6hmKSVpG1faxpUu4wrw4ZdlMyp19oN-5xMAugJe8kLP_rFKe9f94cr0E3KOpFc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512941925</pqid></control><display><type>article</type><title>Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Poon, Darren Ming‐Chun ; Chan, Chi‐Kwok ; Chan, Tim‐Wai ; Cheung, Foon‐Yiu ; Ho, Lap‐Yin ; Kwong, Philip Wai‐Kay ; Lee, Eric Ka‐Chai ; Leung, Angus Kwong‐Chuen ; Leung, Simon Yiu‐Lam ; So, Hing‐Shing ; Tam, Po‐Chor ; Ma, Wai‐Kit</creator><creatorcontrib>Poon, Darren Ming‐Chun ; Chan, Chi‐Kwok ; Chan, Tim‐Wai ; Cheung, Foon‐Yiu ; Ho, Lap‐Yin ; Kwong, Philip Wai‐Kay ; Lee, Eric Ka‐Chai ; Leung, Angus Kwong‐Chuen ; Leung, Simon Yiu‐Lam ; So, Hing‐Shing ; Tam, Po‐Chor ; Ma, Wai‐Kit</creatorcontrib><description>Background
To update the Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer, the same panelists as in the previous consensus panel held a series of meetings to discuss updated clinical evidence and experiences.
Methods
The previous consensus statements were retained, deleted, or revised, and new statements were added. At the final meeting, all statements were reviewed and amended as appropriate, followed by panel voting.
Results
There were significant changes and additions to the previous consensus statements, primarily driven by the advances in androgen receptor signaling inhibitors, treatment sequencing in metastatic castration‐resistant prostate cancer, and increasing recognition of oligometastatic prostate cancer since the introduction of prostate‐specific membrane antigen positron emission tomography. In this update, a total of 59 consensus statements were accepted and established.
Conclusions
The consensus panel updated consensus statements on the management of advanced prostate cancer, aiming to allow physicians in the region to keep abreast of the recent evidence on optimal clinical practices.</description><identifier>ISSN: 1743-7555</identifier><identifier>EISSN: 1743-7563</identifier><identifier>DOI: 10.1111/ajco.13580</identifier><identifier>PMID: 33860645</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Androgen receptors ; Castration ; castration‐naïve prostate cancer ; castration‐resistant prostate cancer ; consensus ; History, 21st Century ; Hong Kong ; Humans ; Male ; Metastases ; metastatic prostate cancer ; Oncology ; Positron emission tomography ; Prostate cancer ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - therapy ; Urology - methods</subject><ispartof>Asia-Pacific journal of clinical oncology, 2021-04, Vol.17 (S3), p.12-26</ispartof><rights>2021 John Wiley & Sons Australia, Ltd</rights><rights>2021 John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3930-b5faf67aeed939347d00afe2f4493aa0536fac272dc39078b9dac9fa26992983</citedby><cites>FETCH-LOGICAL-c3930-b5faf67aeed939347d00afe2f4493aa0536fac272dc39078b9dac9fa26992983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajco.13580$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajco.13580$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,1417,23930,23931,25140,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33860645$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poon, Darren Ming‐Chun</creatorcontrib><creatorcontrib>Chan, Chi‐Kwok</creatorcontrib><creatorcontrib>Chan, Tim‐Wai</creatorcontrib><creatorcontrib>Cheung, Foon‐Yiu</creatorcontrib><creatorcontrib>Ho, Lap‐Yin</creatorcontrib><creatorcontrib>Kwong, Philip Wai‐Kay</creatorcontrib><creatorcontrib>Lee, Eric Ka‐Chai</creatorcontrib><creatorcontrib>Leung, Angus Kwong‐Chuen</creatorcontrib><creatorcontrib>Leung, Simon Yiu‐Lam</creatorcontrib><creatorcontrib>So, Hing‐Shing</creatorcontrib><creatorcontrib>Tam, Po‐Chor</creatorcontrib><creatorcontrib>Ma, Wai‐Kit</creatorcontrib><title>Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates</title><title>Asia-Pacific journal of clinical oncology</title><addtitle>Asia Pac J Clin Oncol</addtitle><description>Background
To update the Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer, the same panelists as in the previous consensus panel held a series of meetings to discuss updated clinical evidence and experiences.
Methods
The previous consensus statements were retained, deleted, or revised, and new statements were added. At the final meeting, all statements were reviewed and amended as appropriate, followed by panel voting.
Results
There were significant changes and additions to the previous consensus statements, primarily driven by the advances in androgen receptor signaling inhibitors, treatment sequencing in metastatic castration‐resistant prostate cancer, and increasing recognition of oligometastatic prostate cancer since the introduction of prostate‐specific membrane antigen positron emission tomography. In this update, a total of 59 consensus statements were accepted and established.
Conclusions
The consensus panel updated consensus statements on the management of advanced prostate cancer, aiming to allow physicians in the region to keep abreast of the recent evidence on optimal clinical practices.</description><subject>Androgen receptors</subject><subject>Castration</subject><subject>castration‐naïve prostate cancer</subject><subject>castration‐resistant prostate cancer</subject><subject>consensus</subject><subject>History, 21st Century</subject><subject>Hong Kong</subject><subject>Humans</subject><subject>Male</subject><subject>Metastases</subject><subject>metastatic prostate cancer</subject><subject>Oncology</subject><subject>Positron emission tomography</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Urology - methods</subject><issn>1743-7555</issn><issn>1743-7563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctKAzEUhoMo3jc-gATciFDNZTLTLEtR6wW6UNfDaSapU2aSOplRuusjCLrw-fokZlov4MIskpOf7_yc5EfogJJTGtYZTJQ7pVx0yRrapknEO4mI-fpPLcQW2vF-QgiXTNJNtMV5NyZxJLbRx8DZMb5pt4fKFW6cKyhwz3uncqhzZxfzt1_kLqi6nmFnWnoxfx1a1TbNsHLWa-sbj30NtS61rT12FtePGpdgYbyU2kbInsEqneFp5ZYsVu29WszfGaESP0yzIPo9tGGg8Hr_69xF9xfn9_1B53Z4edXv3XYUl5x0RsKAiRPQOpNBiJKMEDCamSiSHIAIHhtQLGFZ4EnSHckMlDTAYhn-ost30fHKNkzz1Ghfp2XulS4KsNo1PmWCRjHhMaUBPfqDTlxT2TBcSzEZUclEoE5WlArP85U26bTKS6hmKSVpG1faxpUu4wrw4ZdlMyp19oN-5xMAugJe8kLP_rFKe9f94cr0E3KOpFc</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Poon, Darren Ming‐Chun</creator><creator>Chan, Chi‐Kwok</creator><creator>Chan, Tim‐Wai</creator><creator>Cheung, Foon‐Yiu</creator><creator>Ho, Lap‐Yin</creator><creator>Kwong, Philip Wai‐Kay</creator><creator>Lee, Eric Ka‐Chai</creator><creator>Leung, Angus Kwong‐Chuen</creator><creator>Leung, Simon Yiu‐Lam</creator><creator>So, Hing‐Shing</creator><creator>Tam, Po‐Chor</creator><creator>Ma, Wai‐Kit</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202104</creationdate><title>Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates</title><author>Poon, Darren Ming‐Chun ; Chan, Chi‐Kwok ; Chan, Tim‐Wai ; Cheung, Foon‐Yiu ; Ho, Lap‐Yin ; Kwong, Philip Wai‐Kay ; Lee, Eric Ka‐Chai ; Leung, Angus Kwong‐Chuen ; Leung, Simon Yiu‐Lam ; So, Hing‐Shing ; Tam, Po‐Chor ; Ma, Wai‐Kit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3930-b5faf67aeed939347d00afe2f4493aa0536fac272dc39078b9dac9fa26992983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Androgen receptors</topic><topic>Castration</topic><topic>castration‐naïve prostate cancer</topic><topic>castration‐resistant prostate cancer</topic><topic>consensus</topic><topic>History, 21st Century</topic><topic>Hong Kong</topic><topic>Humans</topic><topic>Male</topic><topic>Metastases</topic><topic>metastatic prostate cancer</topic><topic>Oncology</topic><topic>Positron emission tomography</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Urology - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poon, Darren Ming‐Chun</creatorcontrib><creatorcontrib>Chan, Chi‐Kwok</creatorcontrib><creatorcontrib>Chan, Tim‐Wai</creatorcontrib><creatorcontrib>Cheung, Foon‐Yiu</creatorcontrib><creatorcontrib>Ho, Lap‐Yin</creatorcontrib><creatorcontrib>Kwong, Philip Wai‐Kay</creatorcontrib><creatorcontrib>Lee, Eric Ka‐Chai</creatorcontrib><creatorcontrib>Leung, Angus Kwong‐Chuen</creatorcontrib><creatorcontrib>Leung, Simon Yiu‐Lam</creatorcontrib><creatorcontrib>So, Hing‐Shing</creatorcontrib><creatorcontrib>Tam, Po‐Chor</creatorcontrib><creatorcontrib>Ma, Wai‐Kit</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Asia-Pacific journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poon, Darren Ming‐Chun</au><au>Chan, Chi‐Kwok</au><au>Chan, Tim‐Wai</au><au>Cheung, Foon‐Yiu</au><au>Ho, Lap‐Yin</au><au>Kwong, Philip Wai‐Kay</au><au>Lee, Eric Ka‐Chai</au><au>Leung, Angus Kwong‐Chuen</au><au>Leung, Simon Yiu‐Lam</au><au>So, Hing‐Shing</au><au>Tam, Po‐Chor</au><au>Ma, Wai‐Kit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates</atitle><jtitle>Asia-Pacific journal of clinical oncology</jtitle><addtitle>Asia Pac J Clin Oncol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>17</volume><issue>S3</issue><spage>12</spage><epage>26</epage><pages>12-26</pages><issn>1743-7555</issn><eissn>1743-7563</eissn><abstract>Background
To update the Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer, the same panelists as in the previous consensus panel held a series of meetings to discuss updated clinical evidence and experiences.
Methods
The previous consensus statements were retained, deleted, or revised, and new statements were added. At the final meeting, all statements were reviewed and amended as appropriate, followed by panel voting.
Results
There were significant changes and additions to the previous consensus statements, primarily driven by the advances in androgen receptor signaling inhibitors, treatment sequencing in metastatic castration‐resistant prostate cancer, and increasing recognition of oligometastatic prostate cancer since the introduction of prostate‐specific membrane antigen positron emission tomography. In this update, a total of 59 consensus statements were accepted and established.
Conclusions
The consensus panel updated consensus statements on the management of advanced prostate cancer, aiming to allow physicians in the region to keep abreast of the recent evidence on optimal clinical practices.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33860645</pmid><doi>10.1111/ajco.13580</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1743-7555 |
| ispartof | Asia-Pacific journal of clinical oncology, 2021-04, Vol.17 (S3), p.12-26 |
| issn | 1743-7555 1743-7563 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2514603611 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Androgen receptors Castration castration‐naïve prostate cancer castration‐resistant prostate cancer consensus History, 21st Century Hong Kong Humans Male Metastases metastatic prostate cancer Oncology Positron emission tomography Prostate cancer Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Urology - methods |
| title | Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T12%3A17%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hong%20Kong%20Urological%20Association%E2%80%93Hong%20Kong%20Society%20of%20Uro%E2%80%90Oncology%20consensus%20statements%20on%20the%20management%20of%20advanced%20prostate%20cancer%E2%80%942019%20Updates&rft.jtitle=Asia-Pacific%20journal%20of%20clinical%20oncology&rft.au=Poon,%20Darren%20Ming%E2%80%90Chun&rft.date=2021-04&rft.volume=17&rft.issue=S3&rft.spage=12&rft.epage=26&rft.pages=12-26&rft.issn=1743-7555&rft.eissn=1743-7563&rft_id=info:doi/10.1111/ajco.13580&rft_dat=%3Cproquest_cross%3E2512941925%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512941925&rft_id=info:pmid/33860645&rfr_iscdi=true |